

To: [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl]
From: [redacted] 5.1.2e [redacted] 5.1.2e
Sent: Mon 3/22/2021 3:05:05 PM
Subject: RE: European Science Advisers Call 18 March: Readout
Received: Mon 3/22/2021 3:05:06 PM

Ha [redacted] 5.1.2e

Fijn! Ik heb zojuist gevraagd om je formeel uit te laten nodigen. De eerstvolgende bijeenkomst is a.s. donderdag van 9 tot 10, ik verwacht dat je de uitnodiging snel krijgt vanuit het VK (en zo niet, laat het me even weten, dan stuur ik je de uitnodiging door).

Groeten,
 [redacted] 5.1.2e

From: [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>
Sent: vrijdag 19 maart 2021 11:25
To: [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>
Subject: RE: European Science Advisers Call 18 March: Readout

Ha,

Ik ben net door [redacted] 5.1.2e uitgenodigd om hier bij aan te sluiten. Dat doe ik graag. Kun jij mij de uitnodigingen sturen?
 Dank!! [redacted] 5.1.2e [redacted] 5.1.2e
 Gr [redacted] 5.1.2e

From: [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>
Sent: donderdag 18 maart 2021 18:09
To: [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>
Subject: FW: European Science Advisers Call 18 March: Readout

Weer ter info.

From: [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @go-science.gov.uk>
Sent: donderdag 18 maart 2021 15:38
To: [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e @comite-ethique.fr>; [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e @rivm.nl>; [redacted] 5.1.2e (IfU, GWH <[redacted] 5.1.2e @ethz.ch>; [redacted] 5.1.2e @usb.ch>; [redacted] 5.1.2e @mscbs.es>; [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @dhsc.gov.uk>; [redacted] 5.1.2e @sciensano.be>; [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @rki.de>; [redacted] 5.1.2e @iss.it>; [redacted] 5.1.2e @sfi.ie>; [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @pasteur.fr> <[redacted] 5.1.2e @pasteur.fr>; [redacted] 5.1.2e @chu-lyon. fr <[redacted] 5.1.2e @chu-lyon.fr>; [redacted] 5.1.2e [redacted] 5.1.2e @sciencespo.fr>
Cc: [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e @dhsc.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e ([redacted] 5.1.2e) <[redacted] 5.1.2e @beis.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e (Go Science) <[redacted] 5.1.2e @beis.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e (Go Science) <[redacted] 5.1.2e @go-science.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e (Go Science) <[redacted] 5.1.2e @Go-Science.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @dhsc.gov.uk> [redacted] 5.1.5 [redacted] 5.1.5 @rivm.nl>; [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @comite-ethique.fr>; [redacted] 5.1.2e @rki.de>; [redacted] 5.1.2e [redacted] 5.1.2e ([redacted] 5.1.2e @fcdo.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @sfi.ie>; [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @rivm.nl>; [redacted] 5.1.2e [redacted] 5.1.2e [redacted] 5.1.2e @rki.de>; [redacted] 5.1.2e @iss.it>; [redacted] 5.1.2e [redacted] 5.1.2e <[redacted] 5.1.2e @go-science.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e (BEIS) <[redacted] 5.1.2e @go-science.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e (BEIS) <[redacted] 5.1.2e @go-science.gov.uk>; [redacted] 5.1.2e [redacted] 5.1.2e (BEIS) <[redacted] 5.1.2e @go-science.gov.uk>

Subject: European Science Advisers Call 18 March: Readout

Dear all,

Thank you for attending the call this morning, please see below a readout. We will be in touch confirming the next call.

[redacted] 5.1.2e we will introduce you to the UK testing team in a separate email chain to follow up with a discussion as mentioned this morning.

Best wishes,

5.1.2e

European Advisors Call (18 Mar 2021 0800 – 0900 GMT)

Represented country	Attendee	Job title
UK		Government Chief Scientific Adviser & Chief Medical Officer [CMO]
France	5.1.2e 5.1.2e	Members of the COVID-19 Scientific Council [SC]
Switzerland		Head of Expert Group on International Relations and Head of Expert Group Infection Prevention and Control, Swiss COVID-19 Scientific Taskforce
Belgium	5.1.2e 5.1.2e 5.1.2e	Head of Service - Viral Diseases, Sciensano
Netherlands	5.1.2e 5.1.2e 5.1.2e	Director of the RIVM National Institute for Public Health and the Environment Centre for Infectious Disease Control
Spain		Director of the Coordination Centre for Health Alerts and Emergencies; Ministry of Health
Italy	5.1.2e 5.1.2e	President of the Italian National Institute of Health

Apologies:

5.1.2e 5.1.2e 5.1.2e

Observers:

5.1.2e 5.1.2e 5.1.2e 1.2e 5.1.2e 5.1.2e

5.1.2e

Actions:

- UK to introduce 5.1.2e to the testing team to discuss rollout
- 5.1.2e to share information on the virus strain found in Brittany with her bioinformaticians and share with the group whether this is similar to what was observed in her hospital last Autumn.
- Meeting to be booked in for the coming weeks to discuss outstanding agenda items: Increased mortality associated with UK variant and testing rollout, especially self-testing.

Readout

Colleagues provided an update on the situation in country.

5.1.2a

5.1.2a

5.1.2a

- **Netherlands:** JVD explained the situation is similar to that in Belgium, with incidence of 180 – 200 cases per 100k. The UK variant accounts for 80% of infections, the South African variant is stable at a low figure below 5%. Other variants are being observed but not at any levels of concern. R is above estimated to be between 1.05 and 1.10, over one in part due to the UK variant.

- **UK:** CMO explained that rates are still going down, although it is too early to determine the effects of schools opening on transmission. On variants, the UK variant is dominant, and there are small numbers of the South African and Brazilian variants. We're confident vaccines are working against the UK variant, but effects of the AstraZeneca vaccine on the South African variant are less clear with regards to reducing transmission and preventing against severe disease.
 1. On side effects of the AstraZeneca vaccine, CMO explained that we see no reasons to change our vaccination programme at this time. The risk benefit may change for younger age groups, but for everyone over 50 or with pre-existing conditions, the risk benefit of taking the vaccine is definitely in favour of vaccination for these groups as we're talking about rare side effects of a relatively rare condition.

- **Switzerland:** On variants RS explained the UK variant is the dominant strain, whilst the prevalence of the South African has remained consistently low. Case numbers have recently been on the rise again, and all their models predict there'll be a strong rise in cases over the coming months. RS also mentioned the Swiss government is heavily investing in rolling out testing, and asked for insights from colleagues. PV mentioned we will share contact details of our testing team with RS to follow up the discussion. Following on from Bruno Lina's comments about the cluster in Brittany, ST-S explained that her team made a similar observation at her hospital last autumn - a cluster of about 6 patients with negative nasopharyngeal swabs and positive results from lower respiratory tract samples. Sequencing efforts were hampered by the very low viral load. ST-S commented that she will look at whether there are aspects similar to the situation in France. Bruno shared the characteristics of the variant in Brittany below, and ST-S mentioned she would share with her bioinformaticians and inform the group on any similarities.
 - o GISAID accession numbers: EPI_ISL_1118892, EPI_ISL_1111064 It concerns a variant of clade 20C, with 9 mutations in the spike protein: S:H66D, S:G142V, S:D215G, S:V483A, S:D614G, S:H655Y, S:G669S, S:Q949R, S:N1187D And the following deletions: ORF6:K23-, ORF6:V24-, ORF6:S25-, ORF6:I26-, ORF6:W27-, ORF6:N28-, ORF6:L29-, ORF6:D30-, ORF6:Y31-, S:Y144- The cluster, detected start of January 2021 in a geriatric unit of a hospital of 700 beds, includes 79

cases with symptoms suggestive of COVID-19 as of 13 March (patients and staff; 19 of the infected patients deceased). However, a number of patients with typical symptoms suggesting COVID-19 and a negative RT-PCR test result on nasopharyngeal samples were strongly evocative based on radiography or serology results (56% of the cases had a negative PCR on NP swabs).

- **Italy:** SB explained incidence has been increasing, to over 250 cases per 100k. Italy has been adopting different measures in regions. An increasing number of younger people are being admitted to hospital, with an average age of 43. He is starting to see the positive effects of vaccination rollout amongst healthcare workers and in social care settings. On variants, cases of the South African variant are sporadic, and cases of the Nigerian variant are also being observed. The Brazilian variant is not spreading as fast as expected, the UK variant is the fastest spreading variant. Given the rise in cases, the government has adopted some stricter measures to reduce cases, which will be reviewed again after Easter.

5.1.2a



Government
Office for Science

5.1.2e

Scientific Advisory Group for Emergencies (SAGE)
Government Office for Science

5.1.2e @go-science.gov.uk |

5.1.2e

From: 5.1.2e, 5.1.2e <5.1.2e@comite-ethique.fr>

Sent: 17 March 2021 16:00

To: 5.1.2e, 5.1.2e (5.1.2e, 5.1.2e) <5.1.2e@go-science.gov.uk>; 5.1.2e @rivm.nl; 5.1.2e, 5.1.2e (IfU, GWH

<5.1.2e@ethz.ch>; 5.1.2e @usb.ch; 5.1.2e @mscbs.es; 5.1.2e, 5.1.2e <5.1.2e@dhsc.gov.uk>;

5.1.2e @sciensano.be; 5.1.2e, 5.1.2e <5.1.2e@rki.de>; 5.1.2e @iss.it; 5.1.2e @sfi.ie; 5.1.2e, 5.1.2e

<5.1.2e@pasteur.fr> <5.1.2e@pasteur.fr>; 5.1.2e <5.1.2e@chu-lyon.fr>; 5.1.2e

5.1.2e <5.1.2e@sciencespo.fr>

Cc: 5.1.2e, 5.1.2e <5.1.2e@dhsc.gov.uk>; 5.1.2e, 5.1.2e (5.1.2e) <5.1.2e@beis.gov.uk>; 5.1.2e, 5.1.2e (Go Science)

< 5.1.2e @beis.gov.uk>; 5.1.2e, 5.1.2e (Go Science) < 5.1.2e @go-science.gov.uk>; 5.1.2e, 5.1.2e (Go Science)
 < 5.1.2e @Go-Science.gov.uk>; 5.1.2e, 5.1.2e < 5.1.2e @dhsc.gov.uk> 5.1.5
 < 5.1.5 @rivm.nl>; 5.1.2e, 5.1.2e < 5.1.2e @comite-ethique.fr>; 5.1.2e @rki.de; 5.1.2e, 5.1.2e (5.1.2e
 < 5.1.2e @fcdo.gov.uk>; 5.1.2e, 5.1.2e < 5.1.2e @sfi.ie>; 5.1.2e, 5.1.2e < 5.1.2e @rivm.nl>; 5.1.2e, 5.1.2e
 < 5.1.2e @rki.de>; 5.1.2e @iss.it; 5.1.2e 5.1.2e @go-science.gov.uk>; 5.1.2e
 5.1.2e (BEIS) < 5.1.2e @go-science.gov.uk>; 5.1.2e, 5.1.2e (BEIS) < 5.1.2e @go-
 science.gov.uk>; 5.1.2e, 5.1.2e (BEIS) < 5.1.2e @go-science.gov.uk>; 5.1.2e 5.1.2e < 5.1.2e
 5.1.2e @comite-ethique.fr>

Subject: RE:European Science Advisers Call 18 March: Agenda

Dear all,

I would like to add a question to the agenda: **Why does it work in Spain despite the increase of the UK variant?** Can we have the opinion of 5.1.2e on this?

Also, I am sorry but I will not be present tomorrow. To replace me, I propose :

5.1.2e
 to talk about the immunity passport

Best,

5.1.2e

De : 5.1.2e, 5.1.2e (5.1.2e, 5.1.2e) [5.1.2e @go-science.gov.uk]
Envoyé : mercredi 17 mars 2021 13:30
À : 5.1.2e, 5.1.2e ; 5.1.2e @rivm.nl; 5.1.2e, 5.1.2e (IfU, GWH; 5.1.2e @usb.ch; 5.1.2e @mscbs.es;
 5.1.2e, 5.1.2e ; 5.1.2e @sciensano.be; 5.1.2e, 5.1.2e ; 5.1.2e @iss.it; 5.1.2e @sfi.ie; 5.1.2e, 5.1.2e
 < 5.1.2e @pasteur.fr>
Cc : 5.1.2e, 5.1.2e, 5.1.2e, 5.1.2e (5.1.2e); 5.1.2e, 5.1.2e (Go Science); 5.1.2e, 5.1.2e (Go Science); 5.1.2e, 5.1.2e (Go
 Science); 5.1.2e, 5.1.2e ; 5.1.2e, 5.1.2e, 5.1.2e ; 5.1.2e @rki.de; 5.1.2e, 5.1.2e (5.1.2e ; 5.1.2e, 5.1.2e ; 5.1.2e
 5.1.2e ; 5.1.2e, 5.1.2e ; 5.1.2e @iss.it; 5.1.2e (GO-Science); 5.1.2e, 5.1.2e (BEIS); 5.1.2e
 5.1.2e, 5.1.2e (BEIS); 5.1.2e, 5.1.2e (5.1.2e, 5.1.2e); 5.1.2e, 5.1.2e (BEIS)

Objet : European Science Advisers Call 18 March: Agenda

Dear all,

Please see attached the agenda for tomorrow's European Science Advisers call at 0800 GMT / 0900 CET.

Best wishes,

5.1.2e



5.1.2e
 Scientific Advisory Group for Emergencies (SAGE)
 Government Office for Science
 5.1.2e @go-science.gov.uk 5.1.2e